title: The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth.
abstract: The quinoxaline anti-tumor agent (R+)XK469 mediates its effects by topoisomerase IIB inhibition. This report describes a 14-year old with relapsed neuroblastoma who experienced disease stabilization for 14 months while receiving (R+)XK469 monotherapy. Due to this favorable response, laboratory studies were undertaken to determine efficacy in the preclinical setting. (R+)XK469 inhibited proliferation, caused G(2) cell cycle arrest of neuroblastoma cells in vitro, and inhibited growth of neuroblastoma xenograft tumors. These preclinical results, coupled with the favorable clinical response, demonstrate that (R+)XK469 and similar anti-tumor agents may be effective in the treatment of high-risk neuroblastoma and warrant further testing.
authors.affiliation: Department of Pediatrics, University of Chicago, Chicago, Illinois, USA.
authors.forename: Nisha C
authors.initials: NC
authors.lastname: Kakodkar
authors.forename: Radhika
authors.initials: R
authors.lastname: Peddinti
authors.forename: Morris
authors.initials: M
authors.lastname: Kletzel
authors.forename: Yufeng
authors.initials: Y
authors.lastname: Tian
authors.forename: Lisa J
authors.initials: LJ
authors.lastname: Guerrero
authors.forename: Samir D
authors.initials: SD
authors.lastname: Undevia
authors.forename: David
authors.initials: D
authors.lastname: Geary
authors.forename: Alexandre
authors.initials: A
authors.lastname: Chlenski
authors.forename: Qiwei
authors.initials: Q
authors.lastname: Yang
authors.forename: Helen R
authors.initials: HR
authors.lastname: Salwen
authors.forename: Susan L
authors.initials: SL
authors.lastname: Cohn
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D017809:Fatal Outcome; D006801:Humans; D009362:Neoplasm Metastasis; D009447:Neuroblastoma / Q000188:drug therapy* / Q000473:pathology; D011810:Quinoxalines / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D011810:Quinoxalines; C118180:XK 469